1. Home
  2. HSPO vs HOWL Comparison

HSPO vs HOWL Comparison

Compare HSPO & HOWL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • HSPO
  • HOWL
  • Stock Information
  • Founded
  • HSPO 2014
  • HOWL 2017
  • Country
  • HSPO United States
  • HOWL United States
  • Employees
  • HSPO N/A
  • HOWL N/A
  • Industry
  • HSPO Blank Checks
  • HOWL Biotechnology: Pharmaceutical Preparations
  • Sector
  • HSPO Finance
  • HOWL Health Care
  • Exchange
  • HSPO Nasdaq
  • HOWL Nasdaq
  • Market Cap
  • HSPO 92.0M
  • HOWL 87.4M
  • IPO Year
  • HSPO 2022
  • HOWL 2021
  • Fundamental
  • Price
  • HSPO $11.69
  • HOWL $1.44
  • Analyst Decision
  • HSPO
  • HOWL Strong Buy
  • Analyst Count
  • HSPO 0
  • HOWL 2
  • Target Price
  • HSPO N/A
  • HOWL $9.50
  • AVG Volume (30 Days)
  • HSPO 3.5K
  • HOWL 260.1K
  • Earning Date
  • HSPO 01-01-0001
  • HOWL 03-06-2025
  • Dividend Yield
  • HSPO N/A
  • HOWL N/A
  • EPS Growth
  • HSPO 2.63
  • HOWL N/A
  • EPS
  • HSPO 0.28
  • HOWL N/A
  • Revenue
  • HSPO N/A
  • HOWL $3,386,000.00
  • Revenue This Year
  • HSPO N/A
  • HOWL N/A
  • Revenue Next Year
  • HSPO N/A
  • HOWL $34.17
  • P/E Ratio
  • HSPO $41.53
  • HOWL N/A
  • Revenue Growth
  • HSPO N/A
  • HOWL N/A
  • 52 Week Low
  • HSPO $10.80
  • HOWL $1.26
  • 52 Week High
  • HSPO $12.41
  • HOWL $8.19
  • Technical
  • Relative Strength Index (RSI)
  • HSPO 51.52
  • HOWL 50.05
  • Support Level
  • HSPO $11.70
  • HOWL $1.28
  • Resistance Level
  • HSPO $11.89
  • HOWL $1.60
  • Average True Range (ATR)
  • HSPO 0.07
  • HOWL 0.11
  • MACD
  • HSPO -0.02
  • HOWL 0.03
  • Stochastic Oscillator
  • HSPO 2.38
  • HOWL 55.88

About HSPO Horizon Space Acquisition I Corp.

Horizon Space Acquisition I Corp is a blank check company.

About HOWL Werewolf Therapeutics Inc.

Werewolf Therapeutics Inc is a biopharmaceutical company pioneering the development of therapeutics engineered to stimulate the body's immune system for the treatment of cancer. It is leveraging its proprietary PREDATOR platform to design conditionally activated molecules that stimulate both adaptive and innate immunity with the goal of addressing the limitations of conventional proinflammatory immune therapies. Its INDUKINE molecules are intended to remain inactive in peripheral tissue yet activate selectively in the tumor microenvironment or TME.

Share on Social Networks: